ペプチド癌治療薬の世界市場、用量、価格、売上、臨床試動向：2029年

世界のペプチド癌治療薬の市場規模は、150億米ドルを超える市場機会を有しています。

当レポートは、世界のペプチド癌治療薬市場について調査し、市場の概要とともに、薬剤動向、臨床試験動向、地域別動向、および市場に参入する企業の競合情勢などを提供しています。

目次

第1章 ペプチド治療学のイントロダクション

第2章 世界のペプチド癌治療薬市場に関する洞察

• 現在の市場シナリオ
• 世界のペプチド癌治療薬市場予測

第3章 世界のペプチド癌治療薬市場動向、地域別

• 日本
• 韓国
• 中国
• オーストラリア
• 米国
• 欧州

第4章 市販の癌ペプチド薬に関する洞察- 入手可能性、コスト、用量、適応および特許に関する洞察

• フィルマゴン（デガレリクス）
• エリガード（ロイプロリド）
• リュープロン（酢酸リュープロリド）
• サプレリンLA（酢酸ヒストレリン）
• ゴナックス（酢酸デガレリクス）
• トレルスター（トリプトレリン）
• デカペプチドSR（酢酸トレプトレリンまたはパモ酸トレプトレリン）
• ベルケイド（ボルチゾミブ）
• ニンラロ（イクサゾミブ）
• カイプロリス（カーフィルゾミブ）
• Istodax（ロミデプシン）
• ゾラデックス（ゴセレリン）
• コスメゲン（ダクチノマイシン）
• ソマチュリンデポ（ランレオティド）
• スーパーファクト（ブセレリン）
• サンドスタチン（酢酸オクトレオチド）
• ビンフェジアペン（オクトレオチド）
• メパクト（ミファムルチド）
• ルタセラ（ルテチウムLu 177ドータテート）
• Netspot（ガリウムGa 68ドーテート）

第5章 上市済みの癌ペプチド薬の売上に関する洞察（2019年～2023年）

• リュープロン
• キプロリス
• ゾラデックス
• ルタセラ
• サンドスタチン
• ソマチリン
• デカプチルSR
• ベルケイド
• ニンラロ

第6章 世界のペプチド癌治療臨床試験の概要

• 企業別
• 国別
• 適応症別
• 患者セグメント別
• 相別
• 製剤別

第7章 世界のペプチド癌治療臨床試験の洞察、企業別、国別、適応症別、ペプチドセグメント別

• 調査
• 前臨床
• 第I相
• 第I/II相
• 第II相
• 第II/III相
• 第III相
• 事前登録
• 登録済み

第8章 市販癌ペプチドの臨床的洞察、企業別、国別、および適応症別

第9章 世界のペプチド癌治療市場力学

第10章 治療用ペプチドの標的

• シグナル伝達経路
• 細胞周期の調節
• 細胞死の経路
• 腫瘍抑制タンパク質
• 転写因子

第11章 ペプチド医薬品と従来の癌治療薬の比較

第12章 癌治療におけるペプチドのさまざまなアプローチ

第13章 ペプチド治療法の応用と癌の検出調査手法

• 結腸直腸癌
• 肺癌
• 膵臓癌
• 胃癌
• 乳癌
• 前立腺癌

第14章 ネオアンチゲンワクチン：新たな腫瘍免疫療法

第15章 毒ペプチド：癌ペプチド治療の新時代

第16章 競合情勢

• 3B Pharmaceuticals
• AsclepiX Therapeutics
• Bicycle Therapeutics
• Biohaven Labs
• BrightPath Biotherapeutics
• Bristol-Myers Squibb
• Edinburgh Molecular Imaging
• FogPharma
• GE Healthcare
• Gnubiotics Sciences
• Harvard University
• Heidelberg Pharma AG
• IDP Pharma
• Janux Therapeutics
• Medikine
• Modulation Therapeutics
• Novartis
• PeptiDream
• Pharm-Sintez
• Roche
• Sanofi
• Sapience Therapeutics
• Second Genome
• Viewpoint Molecular Targeting
• Vigeo Therapeutics

List of Figures

• Figure 1-1: Traditional Structure-Based Design Strategies Used in Peptide Drug Discovery
• Figure 1-2: Classification of Anticancer Peptides
• Figure 1-3: Significance of Peptides as Cancer Therapeutics
• Figure 1-4: US - Per Unit Cost of Cancer Drugs (US$)
• Figure 1-5: Role of Peptides in Cancer Immunotherapy
• Figure 2-1: Factors Driving The Global Market Of Cancer Peptides
• Figure 2-2: Countries Leading In Research & Development Of Cancer Peptides
• Figure 2-3: Global - Peptide Therapeutic Market Size (US$ Billion), 2022 - 2029
• Figure 2-4: Global - Peptide Oncology Drugs Market Size (US$ Billion), 2022 - 2029
• Figure 4-1: Firmagon - Patent Issue & Expiration Years
• Figure 4-2: Firmagon - Price per Unit for Supply of 80 mg & 120 mg Powder for Subcutaneous Injection (US$), June'2023
• Figure 4-3: Firmagon - Starting & Maintenance Dosage (mg)
• Figure 4-4: Firmagon - Treatment Costs of Initial Cycle and Maintenance Cycle (US$), June'2023
• Figure 4-5: Eligard - Cost of Different doses of Extended-Release Subcutaneous Powder for Injection (US$), June'2023
• Figure 4-6: Eligard - Recommended Dosage for Prostate Cancer on Monthly Basis (mg)
• Figure 4-7: Eligard - Annual Treatment cost of Prostate Cancer using Different available Doses (US$), June'2023
• Figure 4-8: Lupron - Patent Issue & Expiration Year for Sustained Release Preparation
• Figure 4-9: Lupron - Price for 7.5 mg, 22.5 mg, 30 mg & 40 mg Depot (US$), June'2023
• Figure 4-10: Lupron - Price for 3.75 mg & 11.25 mg Supply of Intramuscular Powder for Injection (US$), June'2023
• Figure 4-11: Lupron - Recommended Dosage for Prostate Cancer Treatment on Monthly Basis (mg)
• Figure 4-12: Lupron - Annual Treatment Cost of Prostate Cancer Treatment using Different Available Doses (US$), June'2023
• Figure 4-13: Histrelin - FDA Approval Years by Brand Name
• Figure 4-14: Supprelin LA - Patent Approval & Expiration Years
• Figure 4-15: Histrelin - Price for Single 50mg Supprelin LA Implant (US$), June'2023
• Figure 4-16: Gonax - Cost of 80mg & 120mg Supply of Powder for Subcutaneous Injection (US$), June'2023
• Figure 4-17: Gonax - Starting & Maintenance Dosage (mg)
• Figure 4-18: Trelstar - Patent Issue & Expiration Year
• Figure 4-19: Trelstar - Cost for a Supply of 3.75mg, 11.25mg & 22.5mg Powder for Intramuscular Injection (US$), June'2023
• Figure 4-20: Trelstar - Recommended Dose for Prostate Cancer Treatment (mg)
• Figure 4-21: Trelstar - Annual Treatment Cost using 3.75 mg, 11.25mg & 22.5mg Powder for Intramuscular Injection (US$), June'2023
• Figure 4-22: Decapeptyl SR - Price for a Supply of 3mg, 11.25mg & 22.5mg Powder for Injection (GBP/US$), June'2023
• Figure 4-23: Decapeptyl SR - Recommended Dosage for Prostate Cancer Treatment on Monthly Basis (mg)
• Figure 4-24: Decapeptyl SR - Annual Treatment Cost of Prostate Cancer Treatment using Different Available Doses (US$), June'2023
• Figure 4-25: Velcade - Price for a Supply of 3.5 mg Powder for Injection (US$), June'2023
• Figure 4-26: Bortizomib - Price for a Supply of 1mg, 2.5mg & 3.5mg Powder for Injection (US$), June'2023
• Figure 4-27: Bortizomib - Price for a Supply of 3.5mg Powder for Intravenous Injection (US$), June'2023
• Figure 4-28: Bortizomib - Price for a Supply of 1.4 mL Powder for Intravenous Solution (US$), June'2023
• Figure 4-29: Ninlaro - Patent Issue & Expiration Years
• Figure 4-30: Ninlaro - Price for 3 Capsule Supply & Price per Unit of Ninlaro Capsule (US$), June'2023
• Figure 4-31: Ninlaro - Recommended Dose & Dose Reductions for Treatment of Multiple Myeloma (Mg/Week)
• Figure 4-32: Kyprolis - Issue & Expiration Years of Patents Assigned to Proteolix Inc
• Figure 4-33: Kyprolis - Issue & Expiration Years of Patent Assigned to Cydex Pharmaceutical
• Figure 4-34: Kyprolis - Issue & Expiration Years of Patents Assigned to Onyx Therapeutics
• Figure 4-35: Kyprolis - Price of 10mg, 30mg & 60mg Intravenous Powder for Injection (US$), June'2023
• Figure 4-36: Kyprolis - Initial Dose & Maintenance Dose for Treatment of Multiple Myeloma (mg/m2/week)
• Figure 4-37: Kyprolis - Initial Dose & Maintenance Dose as Monotherapy for Treatment of Multiple Myeloma (mg/m2 Twice a Week)
• Figure 4-38: Romidepsin - FDA Approval Year by Indication
• Figure 4-39: Romidepsin - Price for a Supply of 10mg Branded & Generic Intravenous Powder (US$), June'2023
• Figure 4-40: Romidepsin- Price for 5.5ml Supply & Price per ml of 5mg/ml Intravenous Solution (US$), June'2023
• Figure 4-41: Romidepsin - Monthly & Yearly Cost Of Treatment (US$), June'2023
• Figure 4-42: Zoladex - Cost of 3.6 mg & 10.8 mg Implant (US$), June'2023
• Figure 4-43: Zoladex - Recommended Dose for Prostate cancer Management on Monthly Basis (mg)
• Figure 4-44: Zoladex - Annual Treatment Cost using 3.6mg & 10.8mg Implant (US$), June'2023
• Figure 4-45: Dactinomycin - Price for Generic & Branded 0.5 mg Powder for Injection (US$), June'2023
• Figure 4-46: Cosmegen - Annual Cost of Wilms Tumor Treatment (US$), June'2023
• Figure 4-47: Somatuline Depot - Price of 60mg/0.2 ml Supply & Price per ml of Somatulin Depot Subcutaneous Solution (US$), June'2023
• Figure 4-48: Somatuline Depot - Price of 90mg/0.3ml Supply & Price per unit of Somatulin Depot Subcutaneous Solution (US$), June'2023
• Figure 4-49: Somatuline Depot - Price of 120mg/0.5ml Supply & Price per unit of Somatulin Depot Subcutaneous Solution (US$), June'2023
• Figure 4-50: Lanreotide - Price of 120mg/0.5ml Supply & Price per unit of Generic Lanreotide Subcutaneous Solution (US$), June'2023
• Figure 4-51: Somatuline Depot - Treatment cost of 1 Cycle & Annual Treatment Cost of GEP-NETs & Carcinoid Syndrome (US$), June'2023
• Figure 4-52: Suprefact - Price of 6.3mg & 9.45mg Depot (US$), June'2023
• Figure 4-53: Suprefact - Cost for a Supply of 1ml/ml Nasal Spray & Injectable solution (US$), June'2023
• Figure 4-54: Suprefact Injection - Recommended Initial Dose & Final Dose for Prostate Cancer Treatment (mg/Day)
• Figure 4-55: Suprefact Depot - Recommended Dose for Prostate Cancer Treatment on Monthly Basis (mg)
• Figure 4-56: Suprefact Depot - Annual Prostate Cancer Treatment Cost (US$), June'2023
• Figure 4-57: Sandostatin - Price for 10 Vial Supply & per Unit Price of 50mcg/ml Injectable Solution (US$), June'2023
• Figure 4-58: Sandostatin - Price for 10 Vial Supply & per Unit Price of 100mcg/ml Injectable Solution (US$), June'2023
• Figure 4-59: Sandostatin - Price for 10 Vial Supply & per Unit Price of 500mcg/ml Injectable Solution (US$), June'2023
• Figure 4-60: Sandostatin LAR - Price for Various Supplies of Intramuscular Powder for Injection (US$), June'2023
• Figure 4-61: Octreotide - Price for 50 mcg/mL Vials of Generic Octreotide Injectable Solution (US$), June'2023
• Figure 4-62: Octreotide - Price for 100 mcg/mL Vials of Generic Octreotide Injectable Solution (US$), June'2023
• Figure 4-63: Octreotide - Price for 200 mcg/mL Vials of Generic Octreotide Injectable Solution (US$), June'2023
• Figure 4-64: Octreotide - Price for 500 mcg/mL Vials of Generic Octreotide Injectable Solution (US$), June'2023
• Figure 4-65: Octreotide - Price for 1000 mcg/mL Vials of Generic Octreotide Injectable Solution (US$), June'2023
• Figure 4-66: Sandostatin - Mean Initial Dose for Treatment of Carcinoid Tumor & Vasoactive Intestinal Peptide Tumor (mg)
• Figure 4-67: Bynfezia Pen - Patent Issue & Expiration Year
• Figure 4-68: Bynfezia Pen - Price for 2.8ml Supply & Price per ml of 2500mcg/ml Subcutaneous Solution (US$), June'2023
• Figure 4-69: Bynfezia Pen - Mean Dose for First 2 Week & Subsequent Weeks (mcg/day)
• Figure 4-70: Mepact - Recommended Number of Dose Administration/ Week for 12 & 24 Weeks Treatment
• Figure 4-71: Germany - Cost of Single Dose & Full Treatment (EUR/US$), June'2023
• Figure 4-72: Lutathera - Patent Issue & Expiration Years
• Figure 4-73: Lutathera - RDP & ODE Regional Expiry Years
• Figure 5-1: Global - Lupron Annual Sales (US$ Million), 2019-2021
• Figure 5-2: US - Lupron Annual Sales (US$ Million), 2019-2021
• Figure 5-3: ROW - Lupron Annual Sales (US$ Million), 2019-2021
• Figure 5-4: Kyprolis - Annual Sales Value (US$ Million), 2018-2023
• Figure 5-5: Kyprolis - Annual Sales by Region (%), Q1'2023
• Figure 5-6: Global - Kyprolis Quarterly Sales Value (US$ Million), 2022
• Figure 5-7: US - Kyprolis Quarterly Sales Value (US$ Million), 2022
• Figure 5-8: ROW - Kyprolis Quarterly Sales Value (US$ Million), 2022
• Figure 5-9: Global - Zoladex Annual Sales (US$ Million), 2019-2023
• Figure 5-10: Regional - Zoladex Annual Sales (US$ Million), 2023
• Figure 5-11: Regional - Zoladex Annual Sales (%), 2023
• Figure 5-12: Global - Zoladex Quarterly Sales (US$ Million), 2022
• Figure 5-13: Regional - Zoladex Annual Sales (US$ Million), 2022
• Figure 5-14: Regional - Zoladex Annual Sales (%), 2022
• Figure 5-15: US - Zoladex Annual Sales (US$ Million), 2019-2023
• Figure 5-16: EU - Zoladex Annual Sales (US$ Million), 2019-2023
• Figure 5-17: EM - Zoladex Annual Sales (US$ Million), 2019-2023
• Figure 5-18: ROW - Zoladex Annual Sales (US$ Million), 2019-2023
• Figure 5-19: Global - Lutathera Annual Sales (US$ Million), 2019-2023
• Figure 5-20: Global - Lutathera Quarterly Sales (US$ Million), 2022
• Figure 5-21: Global - Sandostatin Annual Sales (US$ Million), 2019-2023
• Figure 5-22: Global - Sandostatin Quarterly Sales (US$ Million), 2022
• Figure 5-23: Global - Somatuline Annual Sales (US$ Million), 2019-2023
• Figure 5-24: Global - Somatuline Quarterly Sales (US$ Million), 2022
• Figure 5-25: Global - Decapeptyl Annual Sales (US$ Million), 2019-2023*
• Figure 5-26: Global - Decapeptyl Quarterly Sales (US$ Million), 2022
• Figure 5-27: Global - Velcade Sales Value (US$ Million), 2019-2023
• Figure 5-28: Regional - Velcade Sales Value (US$ Million), 2022
• Figure 5-29: Regional - Velcade Sales Value (%), 2022
• Figure 5-30: Global - Velcade Quarterly Sales Value (US$ Million), 2022
• Figure 5-31: Ninlaro - Annual Sales Value (US$ Million), 2019-2023
• Figure 5-32: Ninlaro - Annual Sales Value (US$ Million), 2022
• Figure 5-33: Ninlaro - Annual Sales by Region (%), Q1'2023
• Figure 5-34: Ninlaro - Annual Sales Value (US$ Million), 2022
• Figure 5-35: Ninlaro - Annual Sales by Region (%), 2022
• Figure 6-1: Global - Peptide Cancer Drug Clinical Pipeline by Company (Number of Drugs), 2021 till 2026
• Figure 6-2: Global - Peptide Cancer Drug Clinical Pipeline by Country (Number of Drugs), 2023
• Figure 6-3: Global - Peptide Cancer Drug Clinical Pipeline by Indication (Number of Drugs), 2023
• Figure 6-4: Global - Peptide Cancer Drug Clinical Pipeline by Patient Segment (Number of 2023
• Figure 6-5: Global - Peptide Cancer Drug Clinical Pipeline by Phase (Number of Drugs), 2023
• Figure 6-6: Global - Peptide Cancer Drug Clinical Pipeline by Drug Formulation (Number of Drugs), 2023
• Figure 9-1: Favorable Market Factors for Cancer Peptide Development
• Figure 9-2: Factors Challenging the Commercialization of Cancer Peptides
• Figure 10-1: Therapeutic Peptides Based on Their Biological Targets
• Figure 10-2: MAPK Signaling Pathways
• Figure 10-3: Cell Cycle in Eukaryotic
• Figure 10-4: Cell Death Pathways
• Figure 10-5: Features of Bcl-2 Family Proteins
• Figure 11-1: Limitations of Monoclonal Antibody
• Figure 11-2: Monoclonal Antibodies & Peptide Therapeutics - Cost of Production per gram (US$)
• Figure 11-3: Pre-Requisite for Gene Therapy
• Figure 11-4: Limitations of Gene Therapy
• Figure 11-5: Drawbacks of Immunotherapy
• Figure 12-1: Different Approaches of Peptide in Cancer Management
• Figure 12-2: Mode of Action - LHRH Agonist & LHRH Antagonist
• Figure 12-3: Effects of Somatostatin Analogs
• Figure 12-4: Peptide Receptor Radionuclide Therapy
• Figure 12-5: Mechanism of Peptide Vaccines
• Figure 13-1: EO2040 - Study Initiation & Expected Completion Year, June'2023
• Figure 13-2: EO4010 - Study Initiation & Competition Year, June'2023
• Figure 13-3: ELI-002 - Study Initiation & Competition Year, June'2023
• Figure 13-4: CBX-12 - Study Initiation & Completion Year'2023
• Figure 13-5: Enterome - OncoMimics Platform
• Figure 13-6: Elicio Therapeutics - The AMP Platform
• Figure 13-7: Alphalex - Selective Targeting of Tumor Cells
• Figure 13-8: Treos Bio - PolyPEPI Approach
• Figure 13-9: UCPVax - Study Initiation & Expected Completion Year, June'2023
• Figure 13-10: GRN-1201 - Study Initiation & Competition Year, June'2023
• Figure 13-11: PeptiCRAd-1 - Study Initiation & Completion Year, June'2023
• Figure 13-12: Owlstone Medical - EVOC Probes for Targeted Assessment of Biological Pathways
• Figure 13-13: Bicycle Therapeutics - Simple Bicycles
• Figure 13-14: Bicycle Therapeutics - Tandems
• Figure 13-15: Bicycle Therapeutics - Higher Order Bicycles
• Figure 13-16: Bicycle Therapeutics - Bicycle Toxin Conjugate
• Figure 13-17: PeptiCRAd - Immunology
• Figure 13-18: T-Win Vaccines - Mechanism of Action
• Figure 13-19: MB1707 - Study Initiation & Completion Year, June'2023
• Figure 13-20: BT5528 - Study Initiation & Completion Year
• Figure 13-21: IMU-131 - Study Initiation & Completion Year
• Figure 13-22: OTSGC-A24 - Study Initiation & Completion Year
• Figure 13-23: Bicycle Therapeutics - Bicycle Toxin Conjugate
• Figure 13-24: HER-Vaxx - Active Immunization Mechanism of Action
• Figure 13-25: Stress-Induced Post-Translational Modifications Cell Surface Peptides
• Figure 13-26: Moditope - Mechanism of Action
• Figure 14-1: Benefits of Neoantigens
• Figure 14-2: Steps of Producing Neoantigen Vaccine
• Figure 14-3: Neoantigen Vaccine - Mode of Action
• Figure 15-1: Advantages of Venom Peptides

“Global Peptide Cancer Drug Market, Dosage, Price, Sales & Clinical Trials Insight 2029” Report Highlights:

• Global Peptide Drug Market Opportunity: > USD 15 Billion
• Marketed Cancer Peptides Drugs Sales Insight 2019 - 2023
• Marketed Cancer Peptides Drugs Dosage, Patent& Price Insight
• Marketed Cancer Peptides Drugs Clinical & Commercial Insight: 25 Drugs
• Peptide Cancer Drug Clinical Trials Insight: > 200 Drugs
• Global Peptide Cancer Drug Clinical Trials Insight By Company, Country Indication & Phase
• Peptide Drug Development Proprietary Technologies By Company & Indication

Biologics have been an important class of drugs for several diseases including cancer. Till now, antibodies have dominated this domain of therapeutics but driven by new technological innovations, researchers have now shifted their new drug development approach towards peptides as preferred choice of anti-cancer agents. For a long time, peptides have been used as therapeutic agents; however, their potential in cancer has been a new area of interest. Due to their ability to offer advanced optimization strategies, peptide drugs have become an attractive area of research.

The development of peptide based drugs and therapies have made great progress in the last decade owing to several pharmaceutical companies developing novel proprietary technologies for producing innovative peptide therapeutics. For instance, South Korea's Nanotechnology and Integrated Bioengineering Centre (NBICE), pharmaceutical company has developed its own novel peptide therapeutic discovery and delivery technology platform called TOPscovery. The company has also created a subsequent clinical pipeline using this novel technology platform which is based on target oriented peptide therapeutic discovery and has target tissue / cell penetrating peptide delivery platform to delivery protein or antibody or siRNA into the target tissue such as that of the cancer cells.

This peptide discovery platform TOPscovery is focused on resolving fibrosis in liver, lung and heart and additionally, the platform technology to target tissue penetrating peptide carrier (NPEP - TPP) can be applied to protein, antibody having intracellular targets, this increase the efficacy and decreases the side effects to non - target. The development of proprietary platforms and novel technologies has been an increasingly important factor that is boosting innovation the today's development of peptide based anti-cancer therapies.

Moreover, the increasing number of companies collaborating and investing in the field is also a signification factor driving the growth of peptide therapeutics. A major reason of this has been the development of novel technologies. With more pharmaceutical companies and biotechs advancing their portfolio with innovative products developed from novel platforms, more companies gain interest in field which could ultimately lead to more collaboration or investment, increasing the overall competitive landscape of the merging global market of anti - cancer peptide therapies.

The trend of collaboration not only extends the research and development capabilities for both the companies but it also allows for assessing the investigational peptide product candidates and likely have an impact on global peptide therapeutic market in terms of increasing the pipeline of cancer peptides, advancements in discovery and optimization of products and the possibility of investigational several different combinational strategies.

For instance, in first quarter of 2023, PeptiDream announced a collaborative arrangement with Ono Pharmaceuticals to discover and develop novel macrocyclic constrained peptide-based drugs directed against targets chosen by Ono. Under the agreement, PeptiDream will apply its proprietary PDPS (Peptide Discovery Platform System) technology to identify and enhance macrocyclic constrained peptide drug candidates, while Ono will develop and commercialize the resulting peptide-based drugs globally under an exclusive license. PeptiDream will be eligible to receive an undisclosed upfront payment in addition to funding to carry out research, as well as added payments based on research, development and commercialization milestones based on global net sales.

In addition, the portfolio of novel cancer peptides with distinct characteristics expands as a result of the development of novel technologies and platforms by various pharmaceutical companies. This will provide diverse market opportunities for each and every therapeutic peptide product candidate. Furthermore, rise in the cancer prevalence and increasing research of the therapeutic use of cancer peptides is likely to be the key factors responsible for the growth of the market. Moreover, the increasing demand for effective and novel therapies can be further anticipated to bring more opportunities and growth in the market. Apart from this, awareness among healthcare professionals and patients about the significant adverse events associated with conventional cancer treatments will also lead to greater adoption towards peptide based therapeutics in cancer treatment.

Our report provides a comprehensive analysis about the current available anti-cancer peptide drugs and therapies while also providing information about their sales insight, patent information and their targeting cancer indication. Additionally, this report also includes the overall market perspective of peptides in different countries and provides a descriptive view on upcoming opportunities that might become available.

Table of Contents

1. Introduction to Peptide Therapeutics

• 1.1 Overview of Peptide Therapeutics
• 1.2 Classification Of Anticancer Peptides
• 1.3 Significance of Peptides as Cancer Therapeutics

2. Global Cancer Peptide Therapeutics Market Insight

• 2.1 Current Market Scenario
• 2.2 Global Cancer Peptide Therapeutics Market Forecast

3. Global Peptide Cancer Therapeutics Market Trend By Region

• 3.1 Japan
• 3.2 South Korea
• 3.3 China
• 3.4 Australia
• 3.5 US
• 3.6 Europe

4. Marketed Cancer Peptides Drugs Insight - Availability, Cost, Dosage, Indication & Patent Insight

• 4.1 Firmagon (Degarelix)
• 4.2 Eligard (Leuprolide)
• 4.3 Lupron (Leuprolide Acetate)
• 4.4 Supprelin LA (Histrelin Acetate)
• 4.5 Gonax (Degarelix Acetate)
• 4.6 Trelstar (Triptorelin)
• 4.7 Decapeptyl SR (Treptorelin Acetate or Pamoate)
• 4.8 Velcade (Bortizomib)
• 4.9 Ninlaro (Ixazomib)
• 4.10 Kyprolis (Carfilzomib)
• 4.11 Istodax (Romidepsin)
• 4.12 Zoladex (Goserelin)
• 4.13 Cosmegen (Dactinomycin)
• 4.14 Somatuline Depot (Lanreotide)
• 4.15 Suprefact (Buserelin)
• 4.16 Sandostatin (Octreotide Acetate)
• 4.17 Bynfezia Pen (Octreotide)
• 4.18 Mepact (Mifamurtide)
• 4.19 Lutathera (Lutetium Lu 177 dotatate)
• 4.20 Netspot (Gallium Ga 68 dotatate)

5. Marketed Cancer Peptides Drugs Sales Insight (2019 -2023)

• 5.1 Lupron
• 5.2 Kyprolis
• 5.3 Zoladex
• 5.4 Lutathera
• 5.5 Sandostatin
• 5.6 Somatuline
• 5.7 Decapeptyl SR
• 5.8 Velcade
• 5.9 Ninlaro

6. Global Peptide Cancer Therapeutics Clinical Trials Overview

• 6.1 By Company
• 6.2 By Country
• 6.3 By Indication
• 6.4 By Patient Segment
• 6.5 By Phase
• 6.6 By Drug Formulation

7. Global Peptide Cancer Therapeutics Clinical Trials Insight By Company, Country, Indication & Peptide Segment

• 7.1 Research
• 7.2 Preclinical
• 7.3 Phase-I
• 7.4 Phase-I/II
• 7.5 Phase-II
• 7.6 Phase-II/III
• 7.7 Phase-III
• 7.8 Preregistration
• 7.9 Registered

8. Marketed Cancer Peptides Clinical Insight by Company, Country & Indication

9. Global Peptide Cancer Therapy Market Dynamics

• 9.1 Favorable Market Parameters
• 9.2 Commercialization Challenges

10. Targets for Therapeutic Peptides

• 10.1 Signal Transduction Pathways
• 10.2 Cell Cycle Regulation
• 10.3 Cell Death Pathways
• 10.4 Tumor Suppressor Protein
• 10.5 Transcription Factors

11. Peptide Drugs v/s Conventional Cancer Therapeutics

• 11.1 Peptide v/s Chemotherapy
• 11.2 Peptide v/s Monoclonal Antibody
• 11.3 Peptide v/s Gene Therapy
• 11.4 Peptide v/s Immunotherapy

12. Different Approaches of Peptides in Cancer Therapeutics

• 12.1 Hormonal Peptides
• 12.2 Peptide as Radionuclide Drug Carrier
• 12.3 Peptide Vaccines
• 12.4 Peptides as Cytotoxic Drug Carrier
• 12.5 Anticancer Peptides
• 12.6 Other Anticancer Drugs Closely Related to Peptides

13. Application of Peptides Therapeutics & Detection Methodology by Cancer

13.1 Colorectal Cancer

• 13.1.1 Peptides in Treatment of Colorectal Cancer
• 13.1.2 Proprietary Technologies

13.2 Lung Cancer

• 13.2.1 Peptides in Treatment of Lung Cancer
• 13.2.2 Proprietary Technologies

13.3 Pancreatic Cancer

• 13.3.1 Peptide in Treatment of Pancreatic Cancer
• 13.3.2 Proprietary Technologies
• 13.4 Gastric Cancer
  • 13.4.1 Peptides in Treatment of Gastric Cancer
  • 13.4.2 Proprietary Technologies
• 13.5 Breast Cancer
  • 13.5.1 Peptides in Treatment of Breast Cancer
  • 13.5.2 Proprietary Technologies
• 13.6 Prostate Cancer
  • 13.6.1 Peptides in Treatment of Prostate Cancer
  • 13.6.2 Proprietary Technologies

14. Neoantigen Vaccine: An Emerging Tumor Immunotherapy

• 14.1 Personalized Neoantigen Based Vaccine in Cancer
• 14.2 Ongoing Clinical Advancements

15. Venom Peptides: New Era for Cancer Peptide Therapy

• 15.1 Relevance of Venom Based Peptide Therapeutics
• 15.2 Recent Clinical Trials & Future Growth Avenues of Venom Peptides

16. Competitive Landscape

• 16.1 3B Pharmaceuticals
• 16.2 AsclepiX Therapeutics
• 16.3 Bicycle Therapeutics
• 16.4 Biohaven Labs
• 16.5 BrightPath Biotherapeutics
• 16.6 Bristol-Myers Squibb
• 16.7 Edinburgh Molecular Imaging
• 16.8 FogPharma
• 16.9 GE Healthcare
• 16.10 Gnubiotics Sciences
• 16.11 Harvard University
• 16.12 Heidelberg Pharma AG
• 16.13 IDP Pharma
• 16.14 Janux Therapeutics
• 16.15 Medikine
• 16.16 Modulation Therapeutics
• 16.17 Novartis
• 16.18 PeptiDream
• 16.19 Pharm-Sintez
• 16.20 Roche
• 16.21 Sanofi
• 16.22 Sapience Therapeutics
• 16.23 Second Genome
• 16.24 Viewpoint Molecular Targeting
• 16.25 Vigeo Therapeutics